Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug

@article{Mahmood1999ClinicalPA,
  title={Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug},
  author={Iftekhar Mahmood and Chandrahas Sahajwalla},
  journal={Clinical Pharmacokinetics},
  year={1999},
  volume={36},
  pages={277-287}
}
Buspirone is an anxiolytic drug given at a dosage of 15 mg/day. The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors. Following a oral dose of buspirone 20mg, the drug is rapidly absorbed. The mean peak plasma concentration (Cmax) is approximately 2.5 μg/L, and the time to reach the peak is under 1 hour. The absolute bioavailability… Expand
6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats
TLDR
Preclinical data suggest that 6-OH-buspirone probably contributes to the clinical efficacy of buspirone as an anxiolytic agent. Expand
Systemic absorption of amitriptyline and buspirone after oral and transdermal administration to healthy cats.
TLDR
Until supporting pharmacokinetic data are available, veterinarians and cat owners should not rely on the transdermal route of administration for treating cats with amitriptyline or buspirone. Expand
Modulation of Cytochrome P450 Activity by 18β‐Glycyrrhetic Acid and its Consequence on Buspirone Pharmacokinetics in Rats
TLDR
Results indicate that GLY can inhibit the in vitro CYP3A‐mediated drug metabolism in RLM via a mixed inhibition mechanism, and shows that GLy could function as merely a weak inhibitor for CYP1‐mediatedDrug metabolism in vivo. Expand
Pharmacokinetics of Buspirone in Autistic Children
TLDR
It is suggested that buspirone is rapidly absorbed and eliminated in young children with extensive metabolism to 1‐PP, and may be useful in developmental disorders in which brain serotonin synthesis is altered. Expand
Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine.
TLDR
Data suggest that buspirone is unlikely to be an effective pharmacotherapy for methamphetamine-use disorder, and it is reasonable for future studies to continue to target these systems. Expand
Pharmacokinetics and Tolerability of Buspirone during Oral Administration to Children and Adolescents with Anxiety Disorder and Normal Healthy Adults
TLDR
Buspirone was generally safe and well tolerated at doses up to 30mgbid in adolescents and adults and most of the children, and the most frequently reported adverse events in children and adolescents were lightheadedness, headache, and dyspepsia. Expand
Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health.
TLDR
Buspirone, paroxetine, and venlafaxine-XR affect upper gastrointestinal functions in healthy humans and support the need for clinical and physiological studies of these agents in functional gastrointestinal disorders. Expand
Understanding the pharmacokinetics of anxiolytic drugs
TLDR
A need for a more balanced assessment of the benefits and risks associated with benzodiazepine use, particularly considering pharmacokinetic profile of the drugs to ensure that patients, who would truly benefit from these agents, are not denied appropriate treatment. Expand
Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT(1A) receptor agonist, using a behavioural model in rats.
TLDR
The study shows that ultrasonic vocalisations can be considered a suitable endpoint for the anxiolytic effect when used in conjunction with non-linear mixed effects modelling to overcome the limited sampling and effect measurements. Expand
Buspirona aumenta a densidade de receptores dopaminérgicos D2- símile em corpo estriado de rato
Buspirone (busp) a piperazinyl derivative with anxiolytic properties is a partial agonist on 5-HT1A with affinity for D2-like dopaminergic receptors (RD2). The objective of this study was to verifyExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Concentrations and effects of buspirone are considerably reduced by rifampicin.
TLDR
Buspirone will most likely show a greatly reduced anxiolytic effect when used together with rifampicin or other potent inducers of CYP3A4 such as phenytoin and carbamazepine. Expand
Metabolism and disposition of buspirone.
TLDR
The pharmacokinetics of buspirone were not significantly different in men and women or in individuals 21 to 40 years old compared with those over 65 years of age and co-administration of amitriptyline or diazepam did not alter the disposition of these agents or their demethylated metabolites. Expand
Lack of Interaction Between Cimetidine and Buspirone
TLDR
The results suggest that within the normal therapeutic dosage ranges for both drugs, it is unlikely that a clinically significant interaction between them will occur. Expand
Dopaminergic effects of buspirone, a novel anxiolytic agent.
TLDR
Data show that, although buspirone has antidopaminergic activity, it can hardly be classified as a classic neuroleptic agent. Expand
Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone.
TLDR
Itraconazole and rifampicin caused only relatively minor changes in the plasma concentrations of the active piperazine metabolite of buspir one, although they had drastic effects on the concentrations of parent buspirone. Expand
Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses
TLDR
In view of high intra-and inter-subject variability in buspirone concentrations, definitive dosing recommendations for patients with compromised renal or hepatic function could not be made, but such patients should initially be dosed cautiously with buspir one. Expand
The relationship between buspirone bioavailability and dose in healthy subjects.
TLDR
It was concluded that buspirone exhibits linear pharmacokinetics following doses in the therapeutic range, and half-life did not change as a function of dose. Expand
Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.
TLDR
Clonidine decreased blood pressure, heart rate, oral body temperature, salivary excretion, plasma noradrenaline, 3,4-dihydroxyphenylglycol (DHPG) concentrations, increased plasma growth hormone but did not modify plasma insulin and C-peptide concentrations. Expand
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
TLDR
If the administration of midazolam cannot be avoided, the dose of midAZolam should be reduced during concomitant treatment with diltiazem and verapamil, as these changes in the pharmacokinetics were associated with profound and prolonged sedative effects. Expand
Lack of Pharmacokinetic Interaction Between Buspirone and Haloperidol in Patients with Schizophrenia
TLDR
The results indicate that coadministration of buspirone does not markedly affect the pharmacokinetics or plasma concentrations of haloperidol. Expand
...
1
2
3
4
5
...